ClinicalTrials.gg
CompletedNCT00644748Updated Feb 2, 2021

A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy

A Phase 4 interventional study of gabapentin in Diabetic Neuropathies, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 10 sites in Brazil. Open to participants aged 51 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
95
Allocation
Non-randomized
Ages
51 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Diabetic Neuropathies by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Diabetic Neuropathies · Viatris Inc..

Enrollment
12th of 12
95 · median 278
Started
2003
the only one that year
Phase 4
4 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Diabetic Neuropathies by Viatris Inc., this one is the 12th largest by enrollment, is the only one that started in 2003, is one of 4 in phase 4, and was the 9th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

None of the 12 studies in Diabetic Neuropathies by Viatris Inc. is open now. The open studies under Diabetic Neuropathies, anywhere →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 51 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetic Neuropathies by Viatris Inc. as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy, safety, and tolerability of gabapentin for the treatment of patients with painful diabetic neuropathy. The quality of life of all treated patients was also assessed.

03

Conditions studied

  • Diabetic Neuropathies

Browse trials for

04

Who can participate

Ages eligible
51 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with stable Diabetes Mellitus 1 or 2
  • Clinical diagnosis of distal symmetric polyneuropathy with a minimum duration of 8 weeks
  • No motor deficits
  • Pain described according to at least one of the following clinical manifestations: burning, cramps or twinges, thermal or mechanical alodinea

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication that may interfere with the assessment of gabapentin during the study or within 7 days of the adminstration of gabapentin
  • Specific systemic diseases or other medical conditions that would interfere with the assessment of gabapentin therapeutic response or safety
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Gabapentin group

    Drug: gabapentin

Interventions

  • Gabapentin oral capsules: Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg

06

What researchers measure

Primary outcomes

  1. Change from baseline Mean Pain Score

    Time frame: Endpoint

Secondary outcomes

  1. Change from baseline Mean Pain Score

    Time frame: Weekly

  2. Proportion of responding patients

    Time frame: Endpoint

  3. Change from baseline Mean Pain Interference with Sleep Score

    Time frame: Weekly and Endpoint

  4. Change from baseline in the 5 sub-scores of the McGill Reduced Pain Questionnaire: the sensory score, the affective score, the total score for pain descriptors, a visual analogue scale, and a scale of Present Pain Intensity

    Time frame: Endpoint

  5. Global Change Impression from the Patient's Point of View

    Time frame: Endpoint

  6. Change from baseline in quality of life

    Time frame: Endpoint

  7. Global Change Impression from the Physician's Point of View

    Time frame: Endpoint

07

Study locations

10 sites
  • Pfizer Investigational Site
    Fortaleza, Ceara 60120-021, Brazil
  • Pfizer Investigational Site
    Taguatinga, DF 72119-900, Brazil
  • Pfizer Investigational Site
    Belo Horizonte, MG 30150-221, Brazil
  • Pfizer Investigational Site
    Curitiba, Parana 80060-150, Brazil
  • Pfizer Investigational Site
    Recife, Pernambuco 52051-380, Brazil
  • Pfizer Investigational Site
    Rio de Janeiro, RJ 20211-340, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01246-903, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04020-041, Brazil
  • Pfizer Investigational Site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2008
First posted
Mar 27, 2008
Start
May 2003
CompletionActual
Aug 2004
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00644748
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
May 2003
Completion
Aug 2004
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion